Bortezomib
Velcade · Proteasome inhibitor · 26S proteasome
Reversible proteasome inhibitor. Blocks the 26S proteasome, leading to accumulation of pro-apoptotic proteins.
Relapsed/refractory MCL
Bortezomib-Induced Myocarditis in a Patient With Multiple Myeloma.
JACC. Case reports · Apr 2026
Gastric Lymphoma
Asia Oceania journal of nuclear medicine & biology · Jan 2026
Highly specific Immunoproteasome inhibitor M3258 induces proteotoxic stress and apoptosis in KMT2A::AFF1 driven acute lymphoblastic leukemia.
Scientific reports · May 2025
Cancer Drug Bortezomib, a Proteasomal Inhibitor, Triggers Cytotoxicity in Microvascular Endothelial Cells via Multi-Organelle Stress.
bioRxiv : the preprint server for biology · Mar 2025
Role of TRIM24 in the regulation of proteasome-autophagy crosstalk in bortezomib-resistant mantle cell lymphoma.
Cell death discovery · Mar 2025
Multisite clinical cross-validation and variant interpretation of a next generation sequencing panel for lymphoid cancer prognostication.
Journal of clinical pathology · Feb 2025
Design of a molecularly imprinted polymer sensor modified with saffron-based copper nanoflowers for highly selective and sensitive determination of bortezomib.
Talanta · Jan 2025
Bortezomib induces Rho-dependent hyperpermeability of endothelial cells synergistically with inflammatory mediators.
BMC pulmonary medicine · Dec 2024
Differential scanning calorimetric domain dissection for HSA upon interaction with Bortezomib: Unveiling the binding dynamics.
International journal of biological macromolecules · Dec 2024
Bortezomib in cancer therapy: Mechanisms, side effects, and future proteasome inhibitors.
Life sciences · Dec 2024
Proteasome inhibition induces apoptosis through simultaneous inactivation of MCL-1/BCL-XL by NOXA independent of CHOP and JNK pathways.
Toxicology · Nov 2024
Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis.
Clinical lymphoma, myeloma & leukemia · Oct 2024
Bioinformatics study of bortezomib resistance-related proteins and signaling pathways in mantle cell lymphoma.
Translational cancer research · Sep 2024
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.
Blood · Sep 2024
Exploiting the potential of the ubiquitin-proteasome system in overcoming tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Genes & diseases · Sep 2024
Synergistic induction of mitotic pyroptosis and tumor remission by inhibiting proteasome and WEE family kinases.
Signal transduction and targeted therapy · Jul 2024
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.
Leukemia · Jun 2024
Assessment of the effects of amphiphilic poly (N‑vinylpyrrolidone) nanoparticles loaded with bortezomib on glioblastoma cell lines and zebrafish embryos.
Biomedical reports · Mar 2024
A phase I study using bortezomib (Velcade), cladribine, and rituximab in treating patients over 50 years old with mantle cell lymphoma.
Frontiers in oncology · Jan 2024
Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer.
PloS one · Jan 2024